Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 15/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709711 | 0.88 | LTB4R2 (0.76) | LTB4R2LPAR1 | |
| SCHEMBL708729 | 0.80 | LTB4R2 (0.81) | LTB4R2AGTR1LPAR1 | |
| SCHEMBL1285722 | 0.78 | LTB4R2 (0.78) | LTB4R2AGTR1LPAR1 | |
| SCHEMBL707952 | 0.77 | LPAR1 (0.79) | LTB4R2LPAR1 | |
| SCHEMBL709238 | 0.77 | LPAR1 (0.85) | LTB4R2LPAR1 | |
| SCHEMBL709794 | 0.77 | LTB4R2 (0.76) | LTB4R2LPAR1 | |
| SCHEMBL2721394 | 0.77 | REN (0.69) | LTB4R2POLBAPEX1TDP1 | |
| SCHEMBL709634 | 0.77 | LPAR1 (0.81) | LTB4R2LPAR1 | |
| SCHEMBL708803 | 0.76 | LTB4R2 (0.89) | LTB4R2AGTR1LPAR1 | |
| SCHEMBL839414 | 0.75 | LTB4R2 (0.81) | LTB4R2AGTR1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LTB4R2 59/4885POLB 1235/4885APEX1 4410/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LTB4R2 59/4885POLB 1235/4885APEX1 4410/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LTB4R2 59/4885POLB 1235/4885APEX1 4410/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | LTB4R2 59/4885POLB 1235/4885APEX1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.